Atul R Mahableshwarkar
Overview
Explore the profile of Atul R Mahableshwarkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jacobsen P, Mahableshwarkar A, Chen Y, Chrones L, Clayton A
J Sex Med
. 2015 Sep;
12(10):2036-48.
PMID: 26331383
Introduction: Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), and does not resolve in most patients. Vortioxetine, an antidepressant with...
12.
Walker V, Patel H, Kurlander J, Essoi B, Yang J, Mahableshwarkar A, et al.
J Manag Care Spec Pharm
. 2015 Aug;
21(9):742-52, 752a-752e.
PMID: 26308222
Background: Major depressive disorder is one of the most common and disabling mental health disorders and is associated with substantial costs in terms of direct health care utilization and workplace...
13.
Mahableshwarkar A, Jacobsen P, Serenko M, Chen Y, Trivedi M
J Clin Psychiatry
. 2015 Jun;
76(5):583-91.
PMID: 26035186
Background: This 8-week, randomized, double-blind, placebo-controlled study, conducted August 2010-May 2012 in the United States, evaluated the safety and efficacy of vortioxetine 10 mg and 15 mg in patients with...
14.
Jacobsen P, Mahableshwarkar A, Serenko M, Chan S, Trivedi M
J Clin Psychiatry
. 2015 Jun;
76(5):575-82.
PMID: 26035185
Context: Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition...
15.
Jacobsen P, Harper L, Chrones L, Chan S, Mahableshwarkar A
Int Clin Psychopharmacol
. 2015 May;
30(5):255-64.
PMID: 26020712
Vortioxetine is approved for the treatment of adults with major depressive disorder. This open-label extension (OLE) study evaluated the safety and tolerability of vortioxetine in the long-term treatment of major...
16.
Mahableshwarkar A, Zajecka J, Jacobson W, Chen Y, Keefe R
Neuropsychopharmacology
. 2015 Feb;
40(8):2025-37.
PMID: 25687662
This multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine (10-20 mg) on cognitive function in adults (aged 18-65 years) diagnosed...
17.
Mahableshwarkar A, Jacobsen P, Chen Y, Serenko M, Trivedi M
Psychopharmacology (Berl)
. 2015 Jan;
232(12):2061-70.
PMID: 25575488
Rationale: Vortioxetine has reduced depressive symptoms in adults with major depressive disorder (MDD) in multiple clinical trials. Objectives: The aim of this study is to evaluate the efficacy, safety, and...
18.
Chappell P, Mahableshwarkar A, Alphs L, Bangs M, Butler A, DuBrava S, et al.
Innov Clin Neurosci
. 2014 Dec;
11(9-10):14-22.
PMID: 25520885
Objective: To survey the current approaches of clinical trial sponsors in prospective suicidal ideation and behavior assessments and challenges encountered. Design: An internet-based survey. Setting: Inclusion of prospective assessments of...
19.
Mahableshwarkar A, Jacobsen P, Serenko M, Chen Y
Hum Psychopharmacol
. 2014 Jan;
29(1):64-72.
PMID: 24424707
Background: Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies. Objective: This double-blind, placebo-controlled study assessed the efficacy and tolerability of vortioxetine in subjects with a...
20.
Alam M, Jacobsen P, Chen Y, Serenko M, Mahableshwarkar A
Int Clin Psychopharmacol
. 2013 Oct;
29(1):36-44.
PMID: 24169027
Patients with major depressive disorder often experience relapse after responding to treatment; therefore, maintenance therapy with antidepressants is recommended for maintaining response or remission. This multicenter, open-label, flexible-dose, 52-week extension...